Selected research
Industry Research
Fenofibrate Industry Research Report 2026
Market perspective
The global Fenofibrate market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Fenofibrate is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Fenofibrate is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Fenofibrate is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Fenofibrate include Teva, Sun Pharmaceutical, Mylan, AbbVie, Vectura, Salix Pharmaceuticals, Rhodes Pharmaceuticals, Prinston Pharmaceutical and Lupin, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Fenofibrate market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Fenofibrate Market by Company
Teva
Sun Pharmaceutical
Mylan
AbbVie
Vectura
Salix Pharmaceuticals
Rhodes Pharmaceuticals
Prinston Pharmaceutical
Lupin
Impax Laboratories
HETERO
Glenmark
Dr. Reddys Laboratories
Cipla
Cipher Pharmaceuticals
Bausch Health
Aurobindo Pharma
APOTEX
Amneal Pharmaceuticals
Fenofibrate Segment by Type
Tablet
Capsule
Fenofibrate Segment by Application
Hospital
Drug Store
Fenofibrate Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Fenofibrate market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Fenofibrate and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Fenofibrate.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Fenofibrate manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Fenofibrate by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Fenofibrate in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Tablet
- Capsule
Applications
- Hospital
- Drug Store
Companies covered
- Teva
- Sun Pharmaceutical
- Mylan
- AbbVie
- Vectura
- Salix Pharmaceuticals
- Rhodes Pharmaceuticals
- Prinston Pharmaceutical
- Lupin
- Impax Laboratories
- HETERO
- Glenmark
- Dr. Reddys Laboratories
- Cipla
- Cipher Pharmaceuticals
- Bausch Health
- Aurobindo Pharma
- APOTEX
- Amneal Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Fenofibrate Market Size (2021-2032)
- 2.2.2 Global Fenofibrate Sales (2021-2032)
- 2.2.3 Global Fenofibrate Market Average Price (2021-2032)
- 2.3 Fenofibrate by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Tablet
- 2.3.3 Capsule
- 2.4 Fenofibrate by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Drug Store
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Fenofibrate Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Fenofibrate Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Fenofibrate Revenue of Manufacturers (2021-2026)
- 3.4 Global Fenofibrate Average Price by Manufacturers (2021-2026)
- 3.5 Global Fenofibrate Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Fenofibrate, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Fenofibrate, Product Type & Application
- 3.8 Global Manufacturers of Fenofibrate, Established Date
- 3.9 Global Fenofibrate Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva
- 4.1.1 Teva Company Information
- 4.1.2 Teva Business Overview
- 4.1.3 Teva Fenofibrate Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Fenofibrate Product Portfolio
- 4.1.5 Teva Recent Developments
- 4.2 Sun Pharmaceutical
- 4.2.1 Sun Pharmaceutical Company Information
- 4.2.2 Sun Pharmaceutical Business Overview
- 4.2.3 Sun Pharmaceutical Fenofibrate Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sun Pharmaceutical Fenofibrate Product Portfolio
- 4.2.5 Sun Pharmaceutical Recent Developments
- 4.3 Mylan
- 4.3.1 Mylan Company Information
- 4.3.2 Mylan Business Overview
- 4.3.3 Mylan Fenofibrate Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Mylan Fenofibrate Product Portfolio
- 4.3.5 Mylan Recent Developments
- 4.4 AbbVie
- 4.4.1 AbbVie Company Information
- 4.4.2 AbbVie Business Overview
- 4.4.3 AbbVie Fenofibrate Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 AbbVie Fenofibrate Product Portfolio
- 4.4.5 AbbVie Recent Developments
- 4.5 Vectura
- 4.5.1 Vectura Company Information
- 4.5.2 Vectura Business Overview
- 4.5.3 Vectura Fenofibrate Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Vectura Fenofibrate Product Portfolio
- 4.5.5 Vectura Recent Developments
- 4.6 Salix Pharmaceuticals
- 4.6.1 Salix Pharmaceuticals Company Information
- 4.6.2 Salix Pharmaceuticals Business Overview
- 4.6.3 Salix Pharmaceuticals Fenofibrate Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Salix Pharmaceuticals Fenofibrate Product Portfolio
- 4.6.5 Salix Pharmaceuticals Recent Developments
- 4.7 Rhodes Pharmaceuticals
- 4.7.1 Rhodes Pharmaceuticals Company Information
- 4.7.2 Rhodes Pharmaceuticals Business Overview
- 4.7.3 Rhodes Pharmaceuticals Fenofibrate Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Rhodes Pharmaceuticals Fenofibrate Product Portfolio
- 4.7.5 Rhodes Pharmaceuticals Recent Developments
- 4.8 Prinston Pharmaceutical
- 4.8.1 Prinston Pharmaceutical Company Information
- 4.8.2 Prinston Pharmaceutical Business Overview
- 4.8.3 Prinston Pharmaceutical Fenofibrate Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Prinston Pharmaceutical Fenofibrate Product Portfolio
- 4.8.5 Prinston Pharmaceutical Recent Developments
- 4.9 Lupin
- 4.9.1 Lupin Company Information
- 4.9.2 Lupin Business Overview
- 4.9.3 Lupin Fenofibrate Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Lupin Fenofibrate Product Portfolio
- 4.9.5 Lupin Recent Developments
- 4.10 Impax Laboratories
- 4.10.1 Impax Laboratories Company Information
- 4.10.2 Impax Laboratories Business Overview
- 4.10.3 Impax Laboratories Fenofibrate Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Impax Laboratories Fenofibrate Product Portfolio
- 4.10.5 Impax Laboratories Recent Developments
- 4.11 HETERO
- 4.11.1 HETERO Company Information
- 4.11.2 HETERO Business Overview
- 4.11.3 HETERO Fenofibrate Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 HETERO Fenofibrate Product Portfolio
- 4.11.5 HETERO Recent Developments
- 4.12 Glenmark
- 4.12.1 Glenmark Company Information
- 4.12.2 Glenmark Business Overview
- 4.12.3 Glenmark Fenofibrate Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Glenmark Fenofibrate Product Portfolio
- 4.12.5 Glenmark Recent Developments
- 4.13 Dr. Reddys Laboratories
- 4.13.1 Dr. Reddys Laboratories Company Information
- 4.13.2 Dr. Reddys Laboratories Business Overview
- 4.13.3 Dr. Reddys Laboratories Fenofibrate Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Dr. Reddys Laboratories Fenofibrate Product Portfolio
- 4.13.5 Dr. Reddys Laboratories Recent Developments
- 4.14 Cipla
- 4.14.1 Cipla Company Information
- 4.14.2 Cipla Business Overview
- 4.14.3 Cipla Fenofibrate Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Cipla Fenofibrate Product Portfolio
- 4.14.5 Cipla Recent Developments
- 4.15 Cipher Pharmaceuticals
- 4.15.1 Cipher Pharmaceuticals Company Information
- 4.15.2 Cipher Pharmaceuticals Business Overview
- 4.15.3 Cipher Pharmaceuticals Fenofibrate Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Cipher Pharmaceuticals Fenofibrate Product Portfolio
- 4.15.5 Cipher Pharmaceuticals Recent Developments
- 4.16 Bausch Health
- 4.16.1 Bausch Health Company Information
- 4.16.2 Bausch Health Business Overview
- 4.16.3 Bausch Health Fenofibrate Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Bausch Health Fenofibrate Product Portfolio
- 4.16.5 Bausch Health Recent Developments
- 4.17 Aurobindo Pharma
- 4.17.1 Aurobindo Pharma Company Information
- 4.17.2 Aurobindo Pharma Business Overview
- 4.17.3 Aurobindo Pharma Fenofibrate Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 Aurobindo Pharma Fenofibrate Product Portfolio
- 4.17.5 Aurobindo Pharma Recent Developments
- 4.18 APOTEX
- 4.18.1 APOTEX Company Information
- 4.18.2 APOTEX Business Overview
- 4.18.3 APOTEX Fenofibrate Sales, Revenue and Gross Margin (2021-2026)
- 4.18.4 APOTEX Fenofibrate Product Portfolio
- 4.18.5 APOTEX Recent Developments
- 4.19 Amneal Pharmaceuticals
- 4.19.1 Amneal Pharmaceuticals Company Information
- 4.19.2 Amneal Pharmaceuticals Business Overview
- 4.19.3 Amneal Pharmaceuticals Fenofibrate Sales, Revenue and Gross Margin (2021-2026)
- 4.19.4 Amneal Pharmaceuticals Fenofibrate Product Portfolio
- 4.19.5 Amneal Pharmaceuticals Recent Developments
5 Global Fenofibrate Market Scenario by Region
- 5.1 Global Fenofibrate Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Fenofibrate Sales by Region: 2021-2032
- 5.2.1 Global Fenofibrate Sales by Region: 2021-2026
- 5.2.2 Global Fenofibrate Sales by Region: 2027-2032
- 5.3 Global Fenofibrate Revenue by Region: 2021-2032
- 5.3.1 Global Fenofibrate Revenue by Region: 2021-2026
- 5.3.2 Global Fenofibrate Revenue by Region: 2027-2032
- 5.4 North America Fenofibrate Market Facts & Figures by Country
- 5.4.1 North America Fenofibrate Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Fenofibrate Sales by Country (2021-2032)
- 5.4.3 North America Fenofibrate Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Fenofibrate Market Facts & Figures by Country
- 5.5.1 Europe Fenofibrate Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Fenofibrate Sales by Country (2021-2032)
- 5.5.3 Europe Fenofibrate Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Fenofibrate Market Facts & Figures by Country
- 5.6.1 Asia Pacific Fenofibrate Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Fenofibrate Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Fenofibrate Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Fenofibrate Market Facts & Figures by Country
- 5.7.1 South America Fenofibrate Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Fenofibrate Sales by Country (2021-2032)
- 5.7.3 South America Fenofibrate Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Fenofibrate Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Fenofibrate Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Fenofibrate Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Fenofibrate Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Fenofibrate Sales by Type (2021-2032)
- 6.1.1 Global Fenofibrate Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Fenofibrate Sales Market Share by Type (2021-2032)
- 6.2 Global Fenofibrate Revenue by Type (2021-2032)
- 6.2.1 Global Fenofibrate Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Fenofibrate Revenue Market Share by Type (2021-2032)
- 6.3 Global Fenofibrate Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Fenofibrate Sales by Application (2021-2032)
- 7.1.1 Global Fenofibrate Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Fenofibrate Sales Market Share by Application (2021-2032)
- 7.2 Global Fenofibrate Revenue by Application (2021-2032)
- 7.2.1 Global Fenofibrate Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Fenofibrate Revenue Market Share by Application (2021-2032)
- 7.3 Global Fenofibrate Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Fenofibrate Value Chain Analysis
- 8.1.1 Fenofibrate Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Fenofibrate Production Mode & Process
- 8.2 Fenofibrate Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Fenofibrate Distributors
- 8.2.3 Fenofibrate Customers
9 Global Fenofibrate Analyzing Market Dynamics
- 9.1 Fenofibrate Industry Trends
- 9.2 Fenofibrate Industry Drivers
- 9.3 Fenofibrate Industry Opportunities and Challenges
- 9.4 Fenofibrate Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst